Pros | - | - | ||
Cons | - | - |
INDMoney rank | - | - | ||
Category,Subcateogry | Equity,Index Funds | Equity,Index Funds | ||
Fund Age | 2 Years | 1 Years | ||
Fund Size | 88 Cr | 3703 Cr | ||
Min Investment | SIP ₹1000 Lumpsum ₹1000 | SIP ₹500 Lumpsum ₹500 | ||
Expense Ratio | 0.37% | 0.44% | ||
Exit Load | 0% | 1% | ||
Benchmark Index | Nifty Pharma TR INR | Nifty India Defence TR INR |
No of Holdings | 22 | 20 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (21.61%) Cipla Ltd (10.88%) Divi's Laboratories Ltd (9.95%) Dr Reddy's Laboratories Ltd (9.59%) Lupin Ltd (5.95%) | Bharat Electronics Ltd (20.62%) Hindustan Aeronautics Ltd Ordinary Shares (20.46%) Solar Industries India Ltd (11.54%) Bharat Forge Ltd (11.5%) Mazagon Dock Shipbuilders Ltd (7.46%) | ||
No of Sectors | 1 | 4 | ||
Top 3 Sectors | Health (100%) | Industrial (71.8%) Consumer Cyclical (12.46%) Basic Materials (12.2%) | ||
Equity % | 99.95% | 99.94% | ||
Debt % | - | - | ||
P/E | 31.82 | 50.97 | ||
P/B | 4.71 | 10.22 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 3.9% | 2.53% | ||
3-Month Return | -3.45% | 2.93% | ||
6-Month Return | 2.65% | 12.89% | ||
1-Year Return | 0.01% | 27.08% | ||
3-Year Return | - | - | ||
5-Year Return | - | - |
Sharpe | - | - | ||
Alpha | - | - | ||
Beta | - | - | ||
Standard Deviation | - | - | ||
Information Ratio | - | - |
Description | ICICI Prudential Nifty Pharma Index Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Motilal Oswal Nifty India Defence Index Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Ashwini Shinde,Nishit Patel | Swapnil Mayekar,Dishant Mehta,Rakesh Shetty |